Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Dose-escalation Study of the Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy Commonly Known as Cellulite

NCT01518907 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT01518907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01518907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Dose-escalation Study of the Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy Commonly Known as Cellulite
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2012
Completion date
February 28, 2013
Enrollment
99 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cellulite, edematous fibrosclerotic panniculopathy